Our results suggested that CCL21-mediated antitumor immunity was strengthened when combined with anti-CD25 mAbs administration, characterized by increasing the frequency of tumor-specific CD8+ T cells and CD11c+ DCs, and enhancing the production of IL-12 and IFN-γ within the tumor, leading to improved antitumor efficacy. Here, CD8A is linked to neoplasm.